SIMTELCIS Trademark

Trademark Overview

On Friday, August 31, 2018, a trademark application was filed for SIMTELCIS with the United States Patent and Trademark Office. The USPTO has given the SIMTELCIS trademark a serial number of 88100618. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 25, 2022. This trademark is owned by Bioverativ Therapeutics Inc.. The SIMTELCIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cold agglutinin disease and chronic immune thrombocytopenia
simtelcis

General Information

Serial Number88100618
Word MarkSIMTELCIS
Filing DateFriday, August 31, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 25, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 22, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cold agglutinin disease and chronic immune thrombocytopenia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 10, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioverativ Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameBioverativ Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Monday, April 25, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 25, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 3, 2021SOU EXTENSION 5 GRANTED
Wednesday, July 28, 2021SOU EXTENSION 5 FILED
Tuesday, August 3, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 28, 2021TEAS EXTENSION RECEIVED
Saturday, January 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 21, 2021SOU EXTENSION 4 GRANTED
Thursday, January 21, 2021SOU EXTENSION 4 FILED
Thursday, January 21, 2021TEAS EXTENSION RECEIVED
Friday, July 31, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 29, 2020SOU EXTENSION 3 GRANTED
Wednesday, July 29, 2020SOU EXTENSION 3 FILED
Wednesday, July 29, 2020TEAS EXTENSION RECEIVED
Thursday, February 27, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 25, 2020SOU EXTENSION 2 GRANTED
Tuesday, February 25, 2020SOU EXTENSION 2 FILED
Tuesday, February 25, 2020TEAS EXTENSION RECEIVED
Thursday, October 10, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 10, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, September 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 3, 2019SOU EXTENSION 1 GRANTED
Tuesday, September 3, 2019SOU EXTENSION 1 FILED
Tuesday, September 3, 2019TEAS EXTENSION RECEIVED
Tuesday, March 19, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 22, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 22, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 2, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 13, 2018ASSIGNED TO EXAMINER
Monday, September 10, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, September 4, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

simtelcis chronic immune thrombocytopenia disease agglutinin preparations treatment cold pharmaceutical